260 related articles for article (PubMed ID: 24246407)
1. A randomised phase 2 study combining LY2181308 sodium (survivin antisense oligonucleotide) with first-line docetaxel/prednisone in patients with castration-resistant prostate cancer.
Wiechno P; Somer BG; Mellado B; Chłosta PL; Cervera Grau JM; Castellano D; Reuter C; Stöckle M; Kamradt J; Pikiel J; Durán I; Wedel S; Callies S; André V; Hurt K; Brown J; Lahn M; Heinrich B
Eur Urol; 2014 Mar; 65(3):516-20. PubMed ID: 24246407
[TBL] [Abstract][Full Text] [Related]
2. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer.
Chi KN; Hotte SJ; Yu EY; Tu D; Eigl BJ; Tannock I; Saad F; North S; Powers J; Gleave ME; Eisenhauer EA
J Clin Oncol; 2010 Sep; 28(27):4247-54. PubMed ID: 20733135
[TBL] [Abstract][Full Text] [Related]
3. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial.
Basch E; Autio K; Ryan CJ; Mulders P; Shore N; Kheoh T; Fizazi K; Logothetis CJ; Rathkopf D; Smith MR; Mainwaring PN; Hao Y; Griffin T; Li S; Meyers ML; Molina A; Cleeland C
Lancet Oncol; 2013 Nov; 14(12):1193-9. PubMed ID: 24075621
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials.
Pond GR; Armstrong AJ; Galsky MD; Wood BA; Leopold L; Sonpavde G
Urol Oncol; 2013 Nov; 31(8):1457-63. PubMed ID: 22552048
[TBL] [Abstract][Full Text] [Related]
5. Rational indication for docetaxel rechallenge in metastatic castration-resistant prostate cancer.
Heck MM; Thalgott M; Retz M; Wolf P; Maurer T; Nawroth R; Hatzichristodoulou G; Gschwend JE; Kübler H
BJU Int; 2012 Dec; 110(11 Pt B):E635-40. PubMed ID: 22889368
[TBL] [Abstract][Full Text] [Related]
6. Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro).
Meulenbeld HJ; van Werkhoven ED; Coenen JL; Creemers GJ; Loosveld OJ; de Jong PC; Ten Tije AJ; Fosså SD; Polee M; Gerritsen W; Dalesio O; de Wit R
Eur J Cancer; 2012 Nov; 48(16):2993-3000. PubMed ID: 22677260
[TBL] [Abstract][Full Text] [Related]
7. The influence of prednisone on the efficacy of docetaxel in men with metastatic castration-resistant prostate cancer.
Teply BA; Luber B; Denmeade SR; Antonarakis ES
Prostate Cancer Prostatic Dis; 2016 Mar; 19(1):72-8. PubMed ID: 26857146
[TBL] [Abstract][Full Text] [Related]
8. A randomised, phase II study of repeated rhenium-188-HEDP combined with docetaxel and prednisone versus docetaxel and prednisone alone in castration-resistant prostate cancer (CRPC) metastatic to bone; the Taxium II trial.
van Dodewaard-de Jong JM; de Klerk JMH; Bloemendal HJ; Oprea-Lager DE; Hoekstra OS; van den Berg HP; Los M; Beeker A; Jonker MA; O'Sullivan JM; Verheul HMW; van den Eertwegh AJM
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1319-1327. PubMed ID: 28421240
[TBL] [Abstract][Full Text] [Related]
9. A multicenter, randomized clinical trial comparing the three-weekly docetaxel regimen plus prednisone versus mitoxantone plus prednisone for Chinese patients with metastatic castration refractory prostate cancer.
Zhou T; Zeng SX; Ye DW; Wei Q; Zhang X; Huang YR; Ye ZQ; Yang Y; Zhang W; Tian Y; Zhou FJ; Jie J; Chen SP; Sun Y; Xie LP; Yao X; Na YQ; Sun YH
PLoS One; 2015; 10(1):e0117002. PubMed ID: 25625938
[TBL] [Abstract][Full Text] [Related]
10. Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer.
Scher HI; Jia X; Chi K; de Wit R; Berry WR; Albers P; Henick B; Waterhouse D; Ruether DJ; Rosen PJ; Meluch AA; Nordquist LT; Venner PM; Heidenreich A; Chu L; Heller G
J Clin Oncol; 2011 Jun; 29(16):2191-8. PubMed ID: 21483004
[TBL] [Abstract][Full Text] [Related]
11. Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5.
Fizazi K; Jones R; Oudard S; Efstathiou E; Saad F; de Wit R; De Bono J; Cruz FM; Fountzilas G; Ulys A; Carcano F; Agarwal N; Agus D; Bellmunt J; Petrylak DP; Lee SY; Webb IJ; Tejura B; Borgstein N; Dreicer R
J Clin Oncol; 2015 Mar; 33(7):723-31. PubMed ID: 25624429
[TBL] [Abstract][Full Text] [Related]
12. Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA.
Oudard S; Fizazi K; Sengeløv L; Daugaard G; Saad F; Hansen S; Hjälm-Eriksson M; Jassem J; Thiery-Vuillemin A; Caffo O; Castellano D; Mainwaring PN; Bernard J; Shen L; Chadjaa M; Sartor O
J Clin Oncol; 2017 Oct; 35(28):3189-3197. PubMed ID: 28753384
[TBL] [Abstract][Full Text] [Related]
13. Abiraterone acetate in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer: U.S. Food and Drug Administration drug approval summary.
Kluetz PG; Ning YM; Maher VE; Zhang L; Tang S; Ghosh D; Aziz R; Palmby T; Pfuma E; Zirkelbach JF; Mehrotra N; Tilley A; Sridhara R; Ibrahim A; Justice R; Pazdur R
Clin Cancer Res; 2013 Dec; 19(24):6650-6. PubMed ID: 24150234
[TBL] [Abstract][Full Text] [Related]
14. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial.
Tannock IF; Fizazi K; Ivanov S; Karlsson CT; Fléchon A; Skoneczna I; Orlandi F; Gravis G; Matveev V; Bavbek S; Gil T; Viana L; Arén O; Karyakin O; Elliott T; Birtle A; Magherini E; Hatteville L; Petrylak D; Tombal B; Rosenthal M;
Lancet Oncol; 2013 Jul; 14(8):760-8. PubMed ID: 23742877
[TBL] [Abstract][Full Text] [Related]
15. A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer.
Hussain M; Rathkopf D; Liu G; Armstrong A; Kelly WK; Ferrari A; Hainsworth J; Joshi A; Hozak RR; Yang L; Schwartz JD; Higano CS
Eur J Cancer; 2015 Sep; 51(13):1714-24. PubMed ID: 26082390
[TBL] [Abstract][Full Text] [Related]
16. Initial biopsy Gleason score as a predictive marker for survival benefit in patients with castration-resistant prostate cancer treated with docetaxel: data from the TAX327 study.
van Soest RJ; de Morrée ES; Shen L; Tannock IF; Eisenberger MA; de Wit R
Eur Urol; 2014 Aug; 66(2):330-6. PubMed ID: 23957945
[TBL] [Abstract][Full Text] [Related]
17. The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer.
Loriot Y; Massard C; Gross-Goupil M; Di Palma M; Escudier B; Bossi A; Chauchereau A; Fizazi K
Eur J Cancer; 2010 Jul; 46(10):1770-2. PubMed ID: 20483588
[TBL] [Abstract][Full Text] [Related]
18. Changes in fPSA level could discriminate tPSA flare-up from tPSA progression in patients with castration-refractory prostate cancer during the initial phase of docetaxel-based chemotherapy.
Du J; Yang Q; Chen XS; Tian J; Yao X
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1055-61. PubMed ID: 24043138
[TBL] [Abstract][Full Text] [Related]
19. Practical guide to the use of chemotherapy in castration resistant prostate cancer.
Petrylak DP
Can J Urol; 2014 Apr; 21(2 Supp 1):77-83. PubMed ID: 24775728
[TBL] [Abstract][Full Text] [Related]
20. Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials Consortium.
Harzstark AL; Rosenberg JE; Weinberg VK; Sharib J; Ryan CJ; Smith DC; Pagliaro LC; Beer TM; Liu G; Small EJ
Cancer; 2011 Jun; 117(11):2419-25. PubMed ID: 24048789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
